City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Warren Chow, MD  
Search results:  3  Clinical trial(s) found  (Page 1 of 1 )
 
Click here to generate a printer-friendly view  
 10040
   P.I.: Warren Chow, MD (Industrial)
Title: The TEAM trial (Tasigna efficacy in advanced melanoma): A randomized, phase III, open label, multi-center, two-arm study to compare the efficacy of Tasigna versus decarbazine (DTIC) in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation
 
Click here for  Full Eligibility Criteria
 08206
   P.I.: Warren Chow, MD (Industrial)
Title: A Randomized, Open-Label, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)
 
Click here for  Full Eligibility Criteria
 04090
   P.I.: Warren Chow, MD (NCI Approved External Peer Review)
Title: A Phase I/II Study of Nelfinavir in Liposarcoma
 
Click here for  Brief Eligibility Criteria
 Full Eligibility Criteria
 

  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and urology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.